

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 May 2008 (02.05.2008)

PCT

(10) International Publication Number
WO 2008/051494 A1

(51) International Patent Classification:

C07D 473/00 (2006.01) **A61K 31/522** (2006.01)
C07D 475/00 (2006.01) **A61P 29/00** (2006.01)
A61K 31/519 (2006.01) **A61P 35/00** (2006.01)

El Camino Real C, San Diego, CA 92130 (US). **RIGGS, Jennifer, R.** [US/US]; 2136 Wales Drive, Cardiff, CA 92007 (US). **PAPA, Patrick, William** [US/US]; 2780 Flower Fields Way, Carlsbad, CA 92010 (US).

(21) International Application Number:

PCT/US2007/022375

(74) Agents: **INSOGNA, Anthony, M.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(22) International Filing Date: 18 October 2007 (18.10.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/853,135 19 October 2006 (19.10.2006) US

(71) Applicant (for all designated States except US): **SIGNAL PHARMACEUTICALS, LLC** [US/US]; 4550 Towne Centre Court, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MORTENSEN, Deborah, Sue** [US/US]; 4001 Datcho Drive, San Diego, CA 92117 (US). **MEDEROS, Maria Mercedes, Delgado** [ES/US]; 7842 Embry Point, San Diego, CA 92126 (US). **SAPIENZA, John, Joseph** [US/US]; 1654 Ridge Rock Court, Chula Vista, CA 91913 (US). **ALBERS, Ronald, J.** [US/US]; 6559 Comly Street, San Diego, CA 92111 (US). **LEE, Branden, G.** [US/US]; 1993 Oxford Court, Vista, CA 92081 (US). **HUANG, Dehua** [CN/US]; 4505 Shorepointe Way, San Diego, CA 92130 (US). **SCHWARZ, Kimberly, Lyn** [US/US]; 4507 Chateau Drive, San Diego, CA 92117 (US). **PARNES, Jason, Simon** [US/US]; 12511


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS



(57) Abstract: Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R^1 , R^2 , L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.